{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:54:09Z","timestamp":1768881249497,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s10120-020-01058-4","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T16:02:32Z","timestamp":1584374552000},"page":"893-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Akinori","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiro","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichiro","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsushi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Akimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"issue":"2","key":"1058_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijrobp.2006.08.070","volume":"67","author":"J Tey","year":"2007","unstructured":"Tey J, Back MF, Shakespeare TP, Mukherjee RK, Lu JJ, Lee KM, et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2007;67(2):385\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"1058_CR2","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00432-009-0553-0","volume":"135","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K, Mayahara H, Takashima A, Nakajima TE, Kato K, Hamaguchi T, et al. Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol. 2009;135(8):1117\u201323.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"22","key":"1058_CR3","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1097\/MD.0000000000000118","volume":"93","author":"J Tey","year":"2014","unstructured":"Tey J, Choo BA, Leong CN, Loy EY, Wong LC, Lim K, et al. Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era. Medicine (Baltimore). 2014;93(22):e118.","journal-title":"Medicine (Baltimore)"},{"issue":"328","key":"1058_CR4","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4.","journal-title":"Sci Transl Med."},{"issue":"10111","key":"1058_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371.","journal-title":"Lancet"},{"issue":"5","key":"1058_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843\u201352.","journal-title":"Immunity"},{"issue":"19","key":"1058_CR7","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","volume":"74","author":"SJ Dovedi","year":"2014","unstructured":"Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458\u201368.","journal-title":"Cancer Res"},{"issue":"7547","key":"1058_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"CT-S Victor","year":"2015","unstructured":"Victor CT-S, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"key":"1058_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-016-0187-0","volume":"4","author":"M Nagasaka","year":"2016","unstructured":"Nagasaka M, Zaki M, Kim H, Raza SN, Yoo G, Lin HS, et al. PD1\/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. J Immunother Cancer. 2016;4:83.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1058_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/15384047.2016.1276133","volume":"18","author":"F Shi","year":"2017","unstructured":"Shi F, Wang X, Teng F, Kong L, Yu J. Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy. Cancer Biol Ther. 2017;18(3):137\u201341.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"1058_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-16-0223","volume":"5","author":"CL Haymaker","year":"2017","unstructured":"Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, et al. Metastatic melanoma patient had a complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol Res. 2017;5(2):100\u20135.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1058_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/PPO.0000000000000181","volume":"22","author":"JE Schoenhals","year":"2016","unstructured":"Schoenhals JE, Seyedin SN, Tang C, Cortez MA, Niknam S, Tsouko E, et al. Preclinical rationale and clinical considerations for radiotherapy plus immunotherapy: going beyond local control. Cancer J. 2016;22(2):130\u20137.","journal-title":"Cancer J"},{"issue":"6","key":"1058_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2326-6066.CIR-15-0238","volume":"4","author":"AK Alomari","year":"2016","unstructured":"Alomari AK, Cohen J, Vortmeyer AO, Chiang A, Gettinger S, Goldberg S, et al. Possible interaction of anti-PD-1 therapy with the effects of radiosurgery on brain metastases. Cancer Immunol Res. 2016;4(6):481\u20137.","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"1058_CR14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"key":"1058_CR15","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S1470-2045(19)30519-4","volume":"20","author":"R Hui","year":"2019","unstructured":"Hui R, Ozguroglu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1670\u201380.","journal-title":"Lancet Oncol."},{"issue":"2","key":"1058_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1058_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00261-008-9420-8","volume":"34","author":"SM Lee","year":"2009","unstructured":"Lee SM, Kim SH, Lee JM, Im SA, Bang YJ, Kim WH, et al. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdom Imaging. 2009;34(4):430\u201340.","journal-title":"Abdom Imaging"},{"key":"1058_CR18","unstructured":"Association Japanese Gastric Cancer. Japanese classification of gastric carcinoma, 15th edn. Tokyo: Kanehara & CO. Ltd.; 2017. (Japanese)"},{"issue":"20","key":"1058_CR19","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA. 2019;116(20):9999\u201310008.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"1058_CR20","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood-2007-06-094656","volume":"110","author":"DQ Tran","year":"2007","unstructured":"Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007;110(8):2983\u201390.","journal-title":"Blood"},{"key":"1058_CR21","first-page":"3","volume":"410","author":"Y Togashi","year":"2017","unstructured":"Togashi Y, Nishikawa H. Regulatory T cells: molecular and cellular basis for immunoregulation. Curr Top Microbiol Immunol. 2017;410:3\u201327.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6","key":"1058_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nm.4086","volume":"22","author":"T Saito","year":"2016","unstructured":"Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22(6):679\u201384.","journal-title":"Nat Med"},{"issue":"8","key":"1058_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41551-018-0203-4","volume":"2","author":"K Lu","year":"2018","unstructured":"Lu K, He C, Guo N, Chan C, Ni K, Lan G, et al. Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy. Nat Biomed Eng. 2018;2(8):600\u201310.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"1058_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","volume":"96","author":"R Qin","year":"2016","unstructured":"Qin R, Olson A, Singh B, Thomas S, Wolf S, Bhavsar NA, et al. Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab. Int J Radiat Oncol Biol Phys. 2016;96(1):72\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1058_CR25","doi-asserted-by":"publisher","first-page":"e0157164","DOI":"10.1371\/journal.pone.0157164","volume":"11","author":"KH Young","year":"2016","unstructured":"Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS ONE. 2016;11(6):e0157164.","journal-title":"PLoS ONE"},{"issue":"4","key":"1058_CR26","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ijrobp.2017.11.029","volume":"100","author":"N Sundahl","year":"2018","unstructured":"Sundahl N, De Wolf K, Kruse V, Meireson A, Reynders D, Goetghebeur E, et al. Phase 1 dose escalation trial of ipilimumab and stereotactic body radiation therapy in metastatic melanoma. Int J Radiat Oncol Biol Phys. 2018;100(4):906\u201315.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1058_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.59125","author":"A Osa","year":"2018","unstructured":"Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, et al. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI. Insight. 2018.https:\/\/doi.org\/10.1172\/jci.insight.59125.","journal-title":"Insight."},{"issue":"4","key":"1058_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","volume":"31","author":"D Eriksson","year":"2010","unstructured":"Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol. 2010;31(4):363\u201372.","journal-title":"Tumour Biol"},{"issue":"suppl 1","key":"1058_CR29","doi-asserted-by":"publisher","first-page":"e557s","DOI":"10.6061\/clinics\/2018\/e557s","volume":"73","author":"HA Carvalho","year":"2018","unstructured":"Carvalho HA, Villar RC. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (Sao Paulo). 2018;73(suppl 1):e557s.","journal-title":"Clinics (Sao Paulo)"},{"issue":"1","key":"1058_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1158\/1078-0432.CCR-14-3110","volume":"22","author":"L Deng","year":"2016","unstructured":"Deng L, Liang H, Fu S, Weichselbaum RR, Fu YX. From DNA damage to nucleic acid sensing: a strategy to enhance radiation therapy. Clin Cancer Res. 2016;22(1):20\u20135.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1058_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12967-019-1872-9","volume":"17","author":"C Liu","year":"2019","unstructured":"Liu C, Hu Q, Hu K, Su H, Shi F, Kong L, et al. Increased CD8+ CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer. J Transl Med. 2019;17(1):120.","journal-title":"J Transl Med"},{"issue":"18","key":"1058_CR32","doi-asserted-by":"publisher","first-page":"26422","DOI":"10.18632\/oncotarget.8389","volume":"7","author":"ZR Yang","year":"2016","unstructured":"Yang ZR, Zhao N, Meng J, Shi ZL, Li BX, Wu XW, et al. Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes. Oncotarget. 2016;7(18):26422\u201335.","journal-title":"Oncotarget"},{"issue":"6","key":"1058_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8_suppl","key":"1058_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1200\/JCO.2019.37.8_suppl.70","volume":"37","author":"OL Ayman","year":"2019","unstructured":"Ayman OL, Shilpa B, David R, Lynn H, Raphael N, Eric C, Sana K. Regulatory T cells mediate resistance to radiotherapy in head and neck squamous cell carcinoma. J Clin Oncol. 2019;37(8_suppl):70.","journal-title":"J Clin Oncol."}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-020-01058-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10120-020-01058-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-020-01058-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T21:06:34Z","timestamp":1615842394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10120-020-01058-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s10120-020-01058-4","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"10 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AS has nothing to disclose. YN reports grants from Ono, grants from Taiho. YT reports personal fees from Ono, personal fees from Bristol-Myers Squibb, personal fees from Chugai, personal fees from AstraZeneca, personal fees from MSD, grants from KOTAI Biotechnology. HK, HH, SK,NN, KT, TK, YY, SM, and KS have nothing to disclose. DK reports personal fees from Takeda, personal fees from Chugai, personal fees from Lilly, personal fees from Merck serono, personal fees from Taiho, personal fees from Sysmex. AK reports grants and personal fees from Taiho, grants from Ono, grants from Sumitomo Dainippon, grants from MSD. YK reports grants and personal fees from Takeda, personal fees from Bayer, personal fees from Lilly, grants and personal fees from Taiho, personal fees from MSD, personal fees from Sanofi, grants from Astra Zeneca, grants from Daiichi Sankyo, grants from Incyte, grants from Ono, grants from Boehringer Ingelheim, grants from Chugai, grants from Amgen, grants from Genmab. HT reports personal fees from Takeda, personal fees from Taiho, personal fees from Chugai, grants from Sysmex, grants from Daiichi Sankyo. TK reports grants and personal fees from MSD, grants from Astellas, grants from Bristol-Myers Squib, grants from Oncolys Biopharma, grants from Ono, grants from Shionogi. TD reports grants and personal fees from Abbie, personal fees from Amgen, personal fees from Bayer, grants and personal fees from Boeringer Ingelheim, grants and personal fees from Daiichi Sankyo, grants and personal fees from MSD, grants and personal fees from Novartis, personal fees from Sumitomo Dainippon, personal fees from Rakuten Medical, grants and personal fees from Taiho, personal fees from Takeda, personal fees from Astellas, grants and personal fees from Bristol-Myers Squibb, personal fees from Oncolys Biopharma, personal fees from Ono, grants from Eisai, grants from kyowa Hakko Kirin, grants from Lilly, grants from Merck Serono, grants from Novartis, grants from Pfizer, grants from Quintiles, grants from Sumitomo Group. TY reports grants and personal fees from Chugai, personal fees from Lilly, personal fees from Merck Serono, grants and personal fees from Sanofi, personal fees from Takeda, personal fees from Merck Biopharma, grants from GlaxoSmithKline, grants from MSD, grants from Nippon Boehringer Ingelheim, grants from Novartis, grants from Ono, grants from Daiichi Sankyo, grants from Parexel, grants from Sumitomo Dainippon. TY reports personal fees from Olympus, personal fees from Mejiseka Pharma, grants from SHIMADZU, grants from HOYA PENTAX, grants from Rakuten Medical. TK and TA has nothing to disclose. HN reports grants and personal fees from Ono, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Chugai, grants from Taiho, grants from Daiichi-Sankyo, grants from Kyowa Kirin, grants from Zenyaku Kogyo, grants from Astellas, grants from Sumitomo Dainippon, grants from Asahi-Kasei, grants from Astellas, grants from BD Japan. KS reports grants and personal fees from Astellas Phama, grants and personal fees from Lilly, personal fees from Bristol-Myers Squibb, personal fees from Takeda, personal fees from Pfizer, grants and personal fees from Ono Pharmaceutical, personal fees from Novartis, personal fees from Abbvie, personal fees from Yakult, grants from Dainippon Sumitomo Pharma, grants from Daiichi Sankyo, grants from Taiho Pharmaceutical, grants from Chugai Phaema, grants and personal fees from MSD, grants from Medi Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed in this study were in accordance with the Declaration of Helsinki of 1964 and later versions and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}